RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Long term survival and immunological correlates in metastatic melanoma treated with IPILIMUMAB 10 mgs within an expanded access program
2012-01-01 DI GIACOMO, ANNA MARIA; Calabro, L; Danielli, R; Pesce, I; Fonsatti, E; Bertocci, E; Giannarelli, D; Biagioli, M; Altomonte, M; Maio, M
Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials
2009-01-01 Maio, M; Lebbe, C; Sileni Chiarion, V; Siegel, J; Hoos, A; Humphrey, R; O'Day, S; Wolchok, J; Weber, J; Harmankaya, K
MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Metastatic Melanoma: Final Results of a Randomized Open-label Phase II Study of the EORTC Melanoma Group (16032-18031)
2009-01-01 Dreno, B; Mortier, L; Robert, C; Chiarion Sileni, V; Testorill, A; Maio, M; Awada, A; Lehmann, F; Kruit, W
Overall Survival (OS) and New Patterns of Response in Patients (Pts) With Advanced Melanoma Treated With Ipilimumab
2008-01-01 O'Day, S; Ibrahim, R; De Pril, V; Maio, M; Chiarion Sileni, V; Gajewski, Tf; Pehamberger, H; Bondarenko, In; Queirolo, P; Lundgren, L; Mikhailov, S; Roman, L; Verschraegen, C; Hoos, A; Humphrey, R; Wolchok, J
P10 lpillimumab in a dose of 10mg/kg improves in patients sith melanoma in stage M1c the disease progression independent of lactat-dehydrogenase (LDH) level
2009-01-01 Smylie, M; Kaehler, Kc; Francis, S; Nyens, B; Maio, M; Minor, D; Verschraegen, C; Chin, K; Ibrahim, R; Hoos, A; Schadendorf, D
P7 Treatment with lpllimumab brings an advantage with reference to long-term survival: reflection rate after 24-months of patients with advanced melanoma from 3 phase II studies with 10mg/kg lpillimumab
2009-01-01 O'Day, Sj; Schadendorf, D; Weber, J; Lebbe, C; Maio, M; Pehamberger, H; Harmankaya, K; Siegel, J; Hoos, A; Humphrey, R; Wolchok, J
Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma
2011-01-01 Robert, C; Thomas, L; Garbe, C; Lebbe, C; Baurain, Jf; Testori, A; Maio, M; Chen, T; Hoos, A; Wolchok, J
Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial
2012-01-01 DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Queirolo, P; Simeone, E; Guidoboni, M; Del Vecchio, M; Ferrucci, Pf; Marasco, A; Fonsatti, E; Annesi, D; Giannarelli, D; Parmiani, G; Maio, M
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma
2012-01-01 Sigalotti, L; Fratta, E; Parisi, G; Covre, A; Sonego, P; Rizzo, A; Colizzi, F; Coral, S; Massarut, S; Maio, M
PROLONGED STABLE DISEASE IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA WHO HAVE PROGRESSED ON PRIOR ANTICANCER THERAPIES
2008-01-01 Chiarion Sileni, V; Hoos, A; Ibrahim, R; Maio, M; Pehamberger, H; Wolchok, J; Humphrey, R; O'Day, S.
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Long term survival and immunological correlates in metastatic melanoma treated with IPILIMUMAB 10 mgs within an expanded access program | 1-gen-2012 | DI GIACOMO, ANNA MARIA; Calabro, L; Danielli, R; Pesce, I; Fonsatti, E; Bertocci, E; Giannarelli, D; Biagioli, M; Altomonte, M; Maio, M | - | |
| Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials | 1-gen-2009 | Maio, M; Lebbe, C; Sileni Chiarion, V; Siegel, J; Hoos, A; Humphrey, R; O'Day, S; Wolchok, J; Weber, J; Harmankaya, K | - | |
| MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Metastatic Melanoma: Final Results of a Randomized Open-label Phase II Study of the EORTC Melanoma Group (16032-18031) | 1-gen-2009 | Dreno, B; Mortier, L; Robert, C; Chiarion Sileni, V; Testorill, A; Maio, M; Awada, A; Lehmann, F; Kruit, W | - | |
| Overall Survival (OS) and New Patterns of Response in Patients (Pts) With Advanced Melanoma Treated With Ipilimumab | 1-gen-2008 | O'Day, S; Ibrahim, R; De Pril, V; Maio, M; Chiarion Sileni, V; Gajewski, Tf; Pehamberger, H; Bondarenko, In; Queirolo, P; Lundgren, L; Mikhailov, S; Roman, L; Verschraegen, C; Hoos, A; Humphrey, R; Wolchok, J | - | |
| P10 lpillimumab in a dose of 10mg/kg improves in patients sith melanoma in stage M1c the disease progression independent of lactat-dehydrogenase (LDH) level | 1-gen-2009 | Smylie, M; Kaehler, Kc; Francis, S; Nyens, B; Maio, M; Minor, D; Verschraegen, C; Chin, K; Ibrahim, R; Hoos, A; Schadendorf, D | - | |
| P7 Treatment with lpllimumab brings an advantage with reference to long-term survival: reflection rate after 24-months of patients with advanced melanoma from 3 phase II studies with 10mg/kg lpillimumab | 1-gen-2009 | O'Day, Sj; Schadendorf, D; Weber, J; Lebbe, C; Maio, M; Pehamberger, H; Harmankaya, K; Siegel, J; Hoos, A; Humphrey, R; Wolchok, J | - | |
| Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma | 1-gen-2011 | Robert, C; Thomas, L; Garbe, C; Lebbe, C; Baurain, Jf; Testori, A; Maio, M; Chen, T; Hoos, A; Wolchok, J | - | |
| Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial | 1-gen-2012 | DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Queirolo, P; Simeone, E; Guidoboni, M; Del Vecchio, M; Ferrucci, Pf; Marasco, A; Fonsatti, E; Annesi, D; Giannarelli, D; Parmiani, G; Maio, M | - | |
| Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma | 1-gen-2012 | Sigalotti, L; Fratta, E; Parisi, G; Covre, A; Sonego, P; Rizzo, A; Colizzi, F; Coral, S; Massarut, S; Maio, M | - | |
| PROLONGED STABLE DISEASE IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA WHO HAVE PROGRESSED ON PRIOR ANTICANCER THERAPIES | 1-gen-2008 | Chiarion Sileni, V; Hoos, A; Ibrahim, R; Maio, M; Pehamberger, H; Wolchok, J; Humphrey, R; O'Day, S. | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 67
- 1 Contributo su Rivista::1.5 Abstract in rivista 67
Data di pubblicazione
- 2010 - 2020 28
- 2000 - 2009 31
- 1995 - 1999 8
Rivista
- ANNALS OF ONCOLOGY 15
- JOURNAL OF CLINICAL ONCOLOGY 11
- EUROPEAN JOURNAL OF CANCER 7
- EUROPEAN JOURNAL OF CANCER. SUPPLEMENT 7
- JOURNAL OF IMMUNOTHERAPY 5
- CELLULAR ONCOLOGY 3
- HUMAN IMMUNOLOGY 3
- JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 3
- ASIA PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2
- JOURNAL OF CLINICAL ONCOLOGY 2
Keyword
- ipilimumab 3
- melanoma 2
- brain metastases 1
- fotemustine 1
- guadecitabina 1
- guadecitabine 1
- nivolumab 1
Lingua
- eng 41
Accesso al fulltext
- no fulltext 60
- reserved 4
- open 3
Appartenenza
- Dipartimento di Biotecnologie Mediche 4
- Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze 67